|Mr. Sanj K. Patel||CEO & Chairman||1.49M||N/A||1970|
|Mr. Stephen Mahoney||Pres & COO||737.86k||N/A||1971|
|Dr. John F. Paolini||Sr. VP & Chief Medical Officer||628.53k||N/A||1965|
|Mr. Chris Heberlig||Exec. VP, CFO & Treasurer||N/A||N/A||1975|
|Mark Ragosa C.F.A.||VP of Investor Relations||N/A||N/A||N/A|
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 9.